#CAPOX
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial www.thelancet.com/journals/lan...
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, op...
In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety ...
www.thelancet.com
October 30, 2026 at 11:03 AM
Had the full brief, including details of possible nasty side effects and all the pills and potions I'll be taking, yesterday so all set to start capox chemotherapy next Friday. Going to take some smellies and see if I can trick myself into believing it's a spa day
September 9, 2026 at 11:10 AM
TNT with short-course radiotherapy followed by CAPOX/FOLFOX achieved excellent long-term local and distant control in high-risk rectal cancer, with particularly favourable outcomes in patients achieving complete response
May 1, 2026 at 7:40 AM
TNT with short-course radiotherapy (5×5 Gy) followed by CAPOX/FOLFOX achieved excellent local and distant control in advanced rectal cancer, possibly driven by optimized surgical margins
April 12, 2026 at 7:13 AM
#Neurotoxicity rates were 46.3% in patients given CapOx, 2.5% in those treated with CapCar, and 0% in those assigned to F-Nal-IrI.

Read More: https://bit.ly/3Zgl5u7
Capecitabine-Carboplatin “Most Favorable” Backbone for Advanced Gastroesophageal Adenocarcinoma
Capecitabine plus oxaliplatin (CapOx) does not offer a progression-free survival (PFS) advantage over capecitabine plus carboplatin (CapCar), nor over nanoliposomal irinotecan, leucovorin and fluorour...
bit.ly
February 13, 2026 at 5:00 AM
[4/5] ABSK061 combined with ABSK043, with or without CAPOX, exhibits good safety and positive anti-tumor activity in patients with FGFR2-positive advanced GC/GEJC, highlighting the potential of
June 26, 2026 at 5:10 AM
[3/5] of the FGFR2/3 inhibitor ABSK061 combined with the oral PD-L1 inhibitor ABSK043, with or without CAPOX (oxaliplatin combined with capecitabine), in the treatment of FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC). Research data shows that
June 26, 2026 at 5:10 AM
Do you know what chemotherapy you will be given?
I had a dual therapy called Capox, but treatments might be different in different countries.
July 21, 2025 at 10:11 PM
Sugemalimab combined with chemotherapy significantly improved survival outcomes for patients with advanced gastric cancer compared to chemotherapy alone.

by Zhang X, Wang J (...) Shen L et 17 al. in JAMA #MedSky

👉 get more here

📖 read the article:
Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
This randomized clinical trial evaluates the efficacy of sugemalimab plus capecitabine and oxaliplatin (CAPOX) vs placebo plus CAPOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with programmed death-ligand 1 combined...
jamanetwork.com
April 24, 2025 at 4:38 PM
Sugemalimab combined with chemotherapy significantly improves survival in patients with advanced gastric cancer, offering hope for better outcomes.

by Zhang X, Wang J (...) Shen L et 17 al. in JAMA #MedSky

📖 read the article:
Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
This randomized clinical trial evaluates the efficacy of sugemalimab plus capecitabine and oxaliplatin (CAPOX) vs placebo plus CAPOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with programmed death-ligand 1 combined...
jamanetwork.com
March 5, 2025 at 8:30 PM
Amazing. Having had Capox last year I’d love to know how it came to be.
July 1, 2025 at 5:59 PM
News stories about medical or scientific “breakthroughs” are often the worst way to find out if there is actually a there there.

The piece seems unclear when the exercise happens. As a bowel cancer patient I can guarantee that a Stage 3 patient on CapOx chemo will not be doing vigorous exercise!
I just can't see how this headline is right. Exercise can, and usually does improve outcomes but this is because chemo patients are often very weak so recovering health and fitness prevents death from non cancer www.theguardian.com/society/2025...
Exercise ‘better than drugs’ to stop cancer returning after treatment, trial finds
First clear evidence that structured exercise regime reduces risk of dying by a third, can stop tumours coming back or a new cancer developing
www.theguardian.com
June 1, 2025 at 5:01 PM
Eine adjuvante Therapie mit drei statt sechs Monaten CAPOX oder FOLFOX führt bei Kolorektalkarzinomen zu keinen Überlebensnachteilen, verringert aber die Langzeittoxizität und verbessert die Lebensqualität. #Darmkrebs #MedSky #Medizin
Drei Monate adjuvante Chemotherapie genügen bei Darmkrebs
Finale Ergebnisse der Studie SCOT
www.springermedizin.de
February 6, 2026 at 7:22 AM
Patient centered #GIonc study

Real world 🌎study
N=153 with adj 💉 #crcsm
<50% completed all #CAPOX - ⬇️ rates for ♀️
⬆️ #tox 🖐️🦶⚡️🔥
More #pallonc needed
@pallonccop.bsky.social @ascocancer.bsky.social

🔗: ascopubs.org/doi/full/10....
April 9, 2025 at 1:32 PM
治療第三期結腸癌的兩種標準術後輔助化療方案:**FOLFOX** 和 **CAPOX**(或稱 XELOX)。

兩者的**總體存活率和無病存活率**在大型臨床試驗中被認為是相似的。主要的區別在於給藥方式、副作用和治療時間:

**CAPOX** 因包含口服藥物而較為方便,但更容易引起**手足症候群和腹瀉**

**FOLFOX** 則較易導致**骨髓抑制和黏膜炎**。

-對於低風險的患者,**CAPOX 三個月**是國際推薦的優選方案,

-高風險患者可能仍需考慮 **FOLFOX 六個月**的治療以獲得更佳療效。
October 11, 2025 at 8:16 PM
Sugemalimab plus chemotherapy improves survival and has a manageable safety profile in advanced gastric or gastroesophageal adenocarcinoma patients.

#MedSky https://ja.ma/4jvErDC
Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
This randomized clinical trial evaluates the efficacy of sugemalimab plus capecitabine and oxaliplatin (CAPOX) vs placebo plus CAPOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with programmed death-ligand 1 combined...
ja.ma
April 17, 2025 at 5:00 PM
A phase III trial (NCT05171660) is underway to validate these findings!

A similar clinical trial can be found at: bmccancer.biomedcentral.com/articles/10....

🌟 Let’s keep pushing the boundaries of #Cancer care!

#Onco404 #MedSky #OncSky
Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer - BMC Cancer
Background This research aimed to assess the efficacy and safety of combining sintilimab with bevacizumab, oxaliplatin, and capecitabine as a primary therapy for patients with RAS-mutated, microsatell...
bmccancer.biomedcentral.com
April 9, 2025 at 3:36 PM
🚀 Exciting results from a phase II trial show sintilimab + bevacizumab, and CAPOX as a promising 1L therapy for RAS-mutant MSS mCRC!🔬

@eclinicalmed.bsky.social @crcequity.bsky.social @cacoloncancer.bsky.social @fightcrc.bsky.social

#Onco404 #Oncology #MedSky #ColorectalCancer #OncSky
April 9, 2025 at 3:36 PM
Feed: "Oncology News, Insights, Stories by OncoDaily"
Published on Saturday, February 28, 2026
Aadil Najeed: Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation
Aadil Najeed: Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation / Aadil Najeed, cancer, Chun-Kang Yang, De-Sen Wan, Dong-Bo Xu, E Xie, Gong Chen,
oncodaily.com
February 28, 2026 at 9:06 PM
May 10, 2026 at 2:11 AM
New @TheLancetOncol - Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus CapOx versus short-course radiotherapy followed by CapOx in patients with locally advanced rectal cancer (SPRING-01)

www.thelancet.com/journals/lan...

#GastroSky #OncSky
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine–oxaliplatin versus short-course radiotherapy followed by capecitabine–oxaliplatin in patients with l...
In patients with locally advanced rectal cancer, short-course radiotherapy combined with sintilimab and capecitabine–oxaliplatin as a total neoadjuvant treatment significantly increased the pathologic...
www.thelancet.com
July 9, 2025 at 3:56 PM
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
December 11, 2025 at 12:30 PM